Latest:
Dr. Subramanian on the Current Standard of Care in Stage III NSCLC
Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jane de Lartigue, PhD
Latest:
Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and Beyond
B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.
Jane Hall, PhD
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology Care
USPSTF guidelines may have decreased the number of patients presenting with prostate
cancer for radiation oncology care, particularly those with low-risk disease, without a
short-term increase in higher-risk disease.
Janet Pregler, MD
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors
For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Janey C. Peterson, MA, MS, RN, EdD
Latest:
There's an App for That: Keeping Patients and Physicians on Track
In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.
Janice Mehnert, MD
Latest:
Dr. Janice Mehnert on Why it's a Challenge to Identify Biomarkers for Immunotherapy
Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discusses challenges with identifying effective biomarkers in for immunotherapy agents.